These are some of the notes I could jot down during today’s conference call.
- Company aims to develop molecules which can offer them a revenue visibility for at least 15- 20 years.
- Potential targeted revenue still stands at1500Cr, no timeline given this time. This number includes revenues from both existing products and products in the pipeline.
- Company wants to invest in energy to save on costs.
- Reasons for lower revenue in FY23 include domestic demand slowdown and inventory correction.
- One important product running at full capacity, while the other will have similar or higher volumes in the coming year.
- Capacity addition through debottlenecking at Derabassi (2000 tonnes) and Laluru plants(1000 tonnes)
- Company expects margins to return to last year’s levels in FY24.
- Focus on R&D to increase product profile.
- Inventory correction is industry-wide, not just for the company.
- Product movement has started, and company expects better margins with lower raw material costs.
Altogether I could not really find clarity in the company’s statements in terms of capacity utilization and domestic demand. Also wanted to understand deeply as to how much of the revenue levels were disturbed due to “adverse climate”. I would be closely tracking the upcoming quarters for a better understanding.
| Subscribe To Our Free Newsletter |
